Alnylam and Merck Scuttle $120M-Plus RNAi Drug-Development Partnership

Sep 19, 2007

NEW YORK (GenomeWeb News) — Alnylam and Merck today said they have ended an ongoing RNAi drug-development alliance, and Alnylam has rescinded its IP grants related to any Merck development programs.

The deal was worth more than $120 million to Alnylam and ended on a mutually agreed upon note. The companies did not elaborate.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

And Deal

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

For Long Life

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

Positive Review

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

This Week in Nucleic Acids Research

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Main menu